Imre Corp. on Friday said it has raised $11.1 million in asecondary offering of 1.85 million units priced at $6. The unitsconsist of three shares of common stock and a warrant topurchase one share of stock. The five-year warrants areredeemable for $2.50 each. After the offering, Seattle-basedImre has 14 million shares of stock outstanding. The offeringwas underwritten by Allen & Co.

Imre stock (NASDAQ:IMRE) closed at $2.25, up 25 cents, onFriday.

The proceeds will be used primarily to fund clinical trials ofImre's Prosorba column, which removes IgG (gamma Gimmunoglobulin) and IgG immune complexes from a patient'splasma outside of the patient's body. The Food and DrugAdministration in August approved clinical studies of Prosorbafor certain cancers, multiple sclerosis, myasthenia gravis andkidney transplant patients. Prosorba has FDA approval to treatidiopathic thrombocytopenic purpura, a bleeding disorder.

(c) 1997 American Health Consultants. All rights reserved.